https://allsci.com/news/licensing-and-partnerships/glp-1-gip-agonist-oral-novo-nordisk-licenses/ AllScien 2026-09-29T14:15:57.365185Z Novo puts up USD 300m for Hengrui's Phase I once-weekly oral GLP-1/GIP agonist https://allsci.com/news/biotech/astrazeneca-summit-investment-ivonescimab/ AllScien 2026-09-29T14:02:00.727605Z AstraZeneca invests USD 2b in Summit to advance ivonescimab-ADC combination trials https://allsci.com/news/biotech/hpk1-protac-degrader-arvinas-enters/ AllScien 2026-09-29T13:09:25.497640Z Arvinas enters immuno-oncology with HPK1 PROTAC degrader in Phase I/II trial https://allsci.com/news/biotech/zenkuda-aflibercept-wamd-achieves-non-inferiority/ AllScien 2026-09-29T13:01:19.450121Z Kodiak’s Zenkuda and tabirafusp-ted meet Phase III endpoints in wet AMD https://allsci.com/news/biotech/car-t-myeloma-response-iaso-bios-dual-targeted/ AllScien 2026-09-29T12:48:04.646120Z IASO Bio’s BCMA/GPRC5D dual-targeted CAR-T RD140 shows 88.9% response rate in Phase I https://allsci.com/news/regulatory-designations-pathways/fda-breakthrough-therapy-designation-grants-to/ AllScien 2026-09-29T12:39:52.997259Z Alume wins FDA Breakthrough Therapy Designation for nerve-visualization agent bevonescein https://allsci.com/news/biotech/nts231-fda-ind-clearance-nutshell-therapeutics/ AllScien 2026-09-29T12:32:46.613091Z Nutshell Therapeutics wins FDA IND clearance for NRF2 degrader NTS231 https://allsci.com/news/biotech/prula-cel-lupus-nephritis-achieves-50-complete/ AllScien 2026-09-29T12:26:16.263095Z Adicet’s prula-cel shows 50% complete renal response rate in Phase I lupus nephritis study https://allsci.com/news/licensing-and-partnerships/lerodalcibep-licensing-agreement-sun-pharma-gains/ AllScien 2026-09-29T11:50:07.027969Z Sun Pharma gains ex-US, ex-China rights to LIB's PCSK9 inhibitor lerodalcibep https://allsci.com/news/licensing-and-partnerships/oral-glp-1-commercialization-mindrank-partners/ AllScien 2026-09-29T10:40:01.066320Z MindRank partners with 3SBio subsidiaries to commercialize AI-designed oral GLP-1 in China https://allsci.com/news/biotech/emugrobart-sma-development-chugai-resurrects-for/ AllScien 2026-09-29T09:41:48.143852Z Chugai resurrects emugrobart in SMA after Roche exits following obesity failure https://allsci.com/news/biotech/brelovitug-phase-iii-hepatitis-delta-mirums-meets/ AllScien 2026-09-28T18:04:22.014829Z Mirum's brelovitug aces Phase III in chronic hepatitis delta virus with 56% response rate https://allsci.com/news/biotech/sirna-therapeutics-rare-diseases-adarx-advances/ AllScien 2026-09-28T17:53:18.768008Z ADARx raises USD 446m in upsized Nasdaq IPO https://allsci.com/news/clinical-trials/carvykti-myeloma-remission-sustains-five-year/ AllScien 2026-09-28T17:42:19.581821Z Carvykti sustains five-year remissions in half of early-line relapsed myeloma patients https://allsci.com/news/licensing-and-partnerships/roche-atavistik-bio-partnership-with-on/ AllScien 2026-09-28T17:37:38.129307Z Roche taps Atavistik Bio in USD 1.9bn allosteric drug discovery deal https://allsci.com/news/licensing-and-partnerships/anti-il-33-antibody-license-tolerance-bio-expands/ AllScien 2026-09-28T17:16:26.709242Z Tolerance Bio adds to thymus pipeline with anti-IL-33 antibody license from Tanabe https://allsci.com/news/biotech/kras-g12d-inhibitor-merck-acquires-preclinical/ AllScien 2026-09-28T17:08:48.755721Z Merck strikes USD 2.13bn deal for China-origin preclinical KRAS G12D inhibitor https://allsci.com/news/biotech/imfinzi-enfortumab-bladder-cancer-fda-grants/ AllScien 2026-09-28T16:42:17.346825Z AstraZeneca wins Priority Review for Imfinzi-EV regimen in bladder cancer https://allsci.com/news/approvals/juvmo-parkinsons-disease-fda-approval-approves/ AllScien 2026-09-28T16:20:41.520153Z AbbVie lands FDA approval for Cerevel-origin Parkinson’s drug Juvmo https://allsci.com/news/biotech/aav-gene-therapy-mucolipidosis-type-iv-umass-chan/ AllScien 2026-09-28T16:19:35.350800Z UMass Chan, Mass General Brigham advance first gene therapy trial in mucolipidosis type IV https://allsci.com/news/biotech/trkb-potentiator-depression-kasvu-therapeutics/ AllScien 2026-09-28T16:03:34.539603Z Finland's Kasvu secures EUR 30m Series A for non-hallucinogenic depression drug https://allsci.com/news/approvals/atebrioz-fda-approval-approves-first-oral-alk2/ AllScien 2026-09-28T15:54:52.933382Z Incyte/Mirum take FDA approval for Atebrioz as first oral ALK2i for fibrodysplasia ossificans progressiva https://allsci.com/news/biotech/fda-clinical-hold-evenamide-stalls-newrons-us/ AllScien 2026-09-28T15:47:22.256921Z FDA keeps Newron’s ENIGMA-TRS 2 study on clinical hold https://allsci.com/news/biotech/hbv-epigenetic-silencer-therapy-nchroma-bios/ AllScien 2026-09-28T15:22:08.178707Z nChroma Bio's epigenetic silencer therapy shows sustained HBV suppression in preclinical models https://allsci.com/news/biotech/pm647-fda-clearance-prime-medicine-receives-for/ AllScien 2026-09-28T13:59:31.365055Z Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency https://allsci.com/news/biotech/ctdna-recovery-am-01-amplifyer-bios-shows-up-to/ AllScien 2026-09-28T13:44:49.062209Z Amplifyer Bio humanized priming agent boosts ctDNA recovery up to 100-fold in mice https://allsci.com/news/approvals/gazyva-fda-approval-nephrotic-syndrome-approves/ AllScien 2026-09-28T13:16:44.228357Z FDA approves Gazyva to reduce relapse risk in pediatric idiopathic nephrotic syndrome https://allsci.com/news/biotech/car-t-therapy-myeloma-iasos-in-vivo-achieves-90/ AllScien 2026-09-28T13:05:14.831936Z IASO Bio’s in vivo BCMA CAR-T posts 90% response rate in first human study https://allsci.com/news/biotech/ifinatamab-deruxtecan-fda-rejection-rejects-bla/ AllScien 2026-09-28T12:04:25.817822Z Daiichi Sankyo, Merck withdraw ifinatamab deruxtecan BLA in ES-SCLC https://allsci.com/news/regulatory-setbacks-safety/aumolertinib-marketing-authorization-revoked/ AllScien 2026-09-28T09:58:10.674240Z EC revokes Hansoh’s aumolertinib approval over data protection breach https://allsci.com/news/business/celularity-funding-recapitalization-closes-usd/ AllScien 2026-09-28T09:25:47.187780Z Celularity raises USD 10m in first tranche of USD 28m recapitalization https://allsci.com/news/business/ligand-avencell-car-t-funding-commits-usd-41m/ AllScien 2026-09-28T09:02:00.588743Z Ligand backs AvenCell CAR-T pipeline with up to USD 47m https://allsci.com/news/business/scancell-blackrock-melanoma-trial-funding/ AllScien 2026-09-28T08:31:09.361907Z Scancell secures USD 25m debt facility from BlackRock to fund iSCIB1+ Phase III melanoma trial